Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genmab | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 92.75B | 20x | 1.35 | DKK 1,462 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 51.11B | -42.1x | 3.19 | DKK 728 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gubra AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 11.55B | -249.6x | 0.58 | DKK 610 | -13.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ViroGates | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 93.59M | -6.2x | -0.24 | DKK 12.10 | -6.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Strategic Partners AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 35.04M | -2.6x | -0.05 | DKK 840 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |